22 March 2013: Clinical Research
Serum resistin and high sensitive CRP levels in patients with subclinical hypothyroidism before and after L-thyroxine therapy
Duygu Yazgan Aksoy BDEF , Nese Cinar BF , Ayla Harmanci BF , Jale Karakaya C , Bulent Okan Yildiz ADE , Aydan Usman AD , Miyase Bayraktar AD
DOI: 10.12659/MSM.883847
Med Sci Monit 2013; 19:210-215
Abstract
BACKGROUND: Subclinical hypothyroidism (SH) is defined by increased thyrotropin (TSH) and normal free thyroxine (fT4) and free triiodothyronine (fT3) levels. Resistin is secreted from adipose tissue and is reported to be associated with insulin resistance and/or inflammation. High sensitive CRP (hs-CRP) is a reliable marker of inflammation. Data related to levels of resistin and hs-CRP in SH and the effect of L-thyroxine treatment on those is limited. We aimed to determine the levels of resistin and hs-CRP in women with SH, and potential effects of L-thyroxine therapy on those levels.
MATERIAL AND METHODS: Thirty-six patients with SH and 27 age- and BMI-matched healthy control women were included. Waist circumference (Wc), waist-to-hip ratio (WHR), resting energy expenditure (REE), fat mass (FM) and lean mass (LM), TSH, free T4 (fT4), free T3 (fT3), total cholesterol (TC), triglycerides (TG), and HDL- and LDL-cholesterol were determined in all participants. Patients received L-thyroxine treatment for 6 months, after which all measurements were repeated. Resistin and hs-CRP levels were studied from frozen samples after the completion of the study.
RESULTS: The 2 groups had similar values for Wc, WHR, FM, LM, TC, TG, HDL-C, LDL-C, resistin, and hs-CRP at the beginning. fT4 were higher, whereas TSH was lower in the control group. Resistin and hs-CRP levels did not change after treatment. hs-CRP correlated with BMI and FM before and after treatment.
CONCLUSIONS: Our results suggest that achievement of euthyroid status by replacement therapy did not change resistin or hs-CRP levels in women with SH. hs-CRP correlated with parameters of obesity, which emphasizes the role of body weight in inflammation.
Keywords: Resistin - blood, Hypothyroidism - drug therapy, C-Reactive Protein - metabolism, Thyrotropin - blood, Thyroxine - therapeutic use, Triiodothyronine - blood
Background
Subclinical hypothyroidism (SH) is defined as a serum thyroid-stimulating hormone (TSH) level above the upper limit of normal despite normal levels of serum free thyroxine. It is common, with a prevalence of 3–8% in the population [1]. Regarding the clinical importance of the disease, there is no clinical evidence related to the adverse effects or the benefits of L-thyroxine therapy for these patients. Patients with thyroid dysfunction frequently show changes in metabolic parameters [2].
Hypothyroidism is associated with lower oxygen expenditure, heat production, and basal metabolic rate. Adipose tissue is a hormonally active system that produces and releases different bioactive substances. Resistin is a peptide hormone synthesized by RSTN gene, belonging to the RELM family. During its discovery, due to its resistance to insulin it has been described as (Resist+in-sulin) [3,4]. Resistin is secreted from adipocytes, muscle, and pancreas cells, but mainly from mononuclear cells [5]. In animal models, resistin has been reported to be associated with insulin resistance and diabetes mellitus, but the exact function in humans is not clear. In obese patients no correlation was present between resistin and insulin sensitivity, but resistin correlated with insulin sensitivity index in obstructive sleep apnea [6–8]. Resistin has proinflammatory cytokine properties and its role in inflammatory diseases independent of insulin resistance had been reported [9]. Resistin is reported to be an independent and strong predictor of major cardio- and cerebrovascular events [10].
C-reactive protein (CRP), named after its ability to precipitate somatic c-polysaccharide of
Material and Methods
Thirty-six women with SH and 27 age- and BMI-matched healthy control women were included. Body weight, waist circumference (Wc), waist-to-hip ratio (WHR), fat mass (FM) and lean mass (LM) quantified by bioelectrical impedance analysis, TSH, fT4, fT3, total cholesterol (TC), triglycerides (TG), HDL-C, LDL-C, fasting glucose and insulin, levels were determined in all participants. Patients with SH who offered treatment received L-thyroxine treatment for 6 months in a prospective design after which all measurements were repeated. Resistin and hs-CRP levels were measured from frozen samples after the completion of the study.
Thyroid function tests are measured using electro chemiluminescent immunoassay (Roche Diagnostics Indianapolis, IN, USA). The functional sensitivity of the TSH assay was 0.014 μIU/ml (range 0.005–100 μIU/ml). Normal range of thyroid tests were TSH – 0.27–4.2 mIU/mL, and free T4 – 12–22 pmol/L). Patients with TSH levels between 4.2 to 10 mIU/mL with normal FT4 values are accepted to have SH.
Serum lipids are measured by enzymatic calorimetric method. LDL-C is calculated with the Friedwald formula. Plasma glucose is measured with a spectrometric analyzer with glucose oxidase method and insulin levels are measured with immunoradiometric assay Immunotech IRMA, Czech Republic) [Intraassay coefficient of variation (CV) 4.3%, interassay CV 3.4%]. Insulin sensitivity HOMA (homeostasis model assessment) is calculated as [fasting plasma glucose (mmol/l)x fasting plasma insulin]/ 22.5 [15].
Body composition is measured after an overnight fast with bioimpedance analysis using TANITA (Tanita, BC-418 MA type segmental body analysis monitor, Japan). Total body fat and truncal fat percentage, fat and lean mass (kg) were recorded.
Resistin is measured with ELISA from frozen samples (Biovendor, Human Resistin Elisa, Biovendor Laboratorni Medicina, Czech Republic) (Sensitivity 0.033 ng/ml, test limit 50 ng/ml, intra-assay variation 2.8–3.4%, inter- assay variation 5.1–6.9%).
hs-CRP is measured with the highly sensitive near infrared particle immunoassay rate- method (Immage®Immunochemistry Systems CRPH test, Beckman-Coulter Galway, Ireland). Ninety-five percent of population levels were less than 0.744 mg/dl. Interassay variation was ≤0.011 mg/dl, with 20% functional sensitivity.
All statistical analyses were performed using SPSS 13.0 (SPSS, Chicago, IL, USA). All data are presented as mean ±SD. Student t test and paired-sample t test, Mann Whitney and Wilcoxon tests were used to compare groups where appropriate. P<0.05 was considered significant.
Results
Thirty-six women with SH and 27 healthy sex- and-age matched controls were included in the study. All anthropometric, clinical and laboratory parameters were recorded (Table 1). Patients with SH had higher TSH and lower fT4 levels compared to the control group (Table 2). The rest of the parameters, including resistin and hs-CRP, were similar between groups.
All women with SH were placed on L-thyroxine for 6 months. The results were available for 34 patients after they had reached euthyroid status. L-T4 treatment decreased TSH and increased fT4 significantly (p<0.0001 and p<0.0001, respectively), but did not change the rest of the parameters (Table 3). LT4 treatment did not change either resistin or hs-CRP levels (Table 4).
Resistin levels correlated positively with hs-CRP (p=0.034 and Rs=0.355) at the beginning of the study (p=0.012, Rs=−0.426; and p=0.028, and Rs=−0.382, respectively). Basal hs-CRP correlated positively with weight, BMI, waist, WHR, FM and TG (Table 5).
Resistin did not correlate with any of the parameters at the end of the study; on the other hand, hs-CRP correlated with BMI, WHR, FM, TG, and HOMA at the end of the study (Table 6).
Discussion
Our results suggest that women with SH have similar resistin and hs-CRP levels in comparison with age- and BMI-matched healthy women. Achievement of euthyroid status by replacement therapy did not change any of these parameters.
SH is a unique disease because it is presented with a sole increase in TSH, but normal free thyroid hormone levels. CRP has been studied previously in SH [12,13,16–22]. Some studies reported an increase in SH [13,18], but the rest of them could not find any change compared to control groups [17,19,21–23]. We could not demonstrate a difference in hs-CRP levels in women with SH compared to the control group, and treatment with LT4 did not have any effect on these parameters. In spite of the absence of any difference between the control group and patients with SH, hs-CRP correlated with weight-related parameters. Adipose tissue is more frequently mentioned in the pathogenesis of inflammation [24]. CRP levels are closely associated with parameters of adiposity, insulin resistance, and metabolic syndrome [25–27]. Presence of inflammatory cells in the adipose tissue may be the cause of changes, even if we were not able to demonstrate any difference in amount of the adipose tissue [28,29]. The interactions between the metabolic pathways and inflammation occurring through an activation of the adipose tissue still remains mysterious.
Adipokines (leptin and adiponectin) had been studied in SH and controversial results had been reported. There is only limited data available related to resistin, a unique molecule regarding its role in insulin sensitivity and inflammation in thyroid disorders. As a product of adipose tissue, resistin has some role beyond that of other adipokines [30–35]. Resistin plays an important role in the pathogenesis of obesity-related insulin resistance and type 2 diabetes mellitus in animal models, but its precise role in humans is debatable [3,36–38]. Resistin has some proinflammatory cytokine properties and plays an important role in inflammatory diseases irrespective of its role in insulin resistance. It has been suggested that resistin modulates molecular pathways that maintain cross-talk between inflammation and metabolic markers [9]. Thyroid hormone abnormalities and resistin interference has been studied in different diseases [14,29,39–41]. Botella-Carretero et al. demonstrated an increase in resistin and TSH in thyroid cancer patients during withdrawal of thyroid hormones for iodine scan, but this increase was not different from the control group [39]. Krassas et al could not demonstrate a relationship between resistin and thyroid hormone status [42]. High doses of triiodothyronine did not have any effect on resistin, whereas diminished leptin and adiponectin gene expression in calorie-restricted obese rats [43]. Contrary to this, a positive correlation between resistin, fT3, and fT4 had been documented by Yaturu et al. [14]. In a study including 43 hyperthyroid and 23 control patients, resistin levels were higher in hyperthyroid patients and decreased after restoration of the thyroid hormone levels [40]. This was supported by results of a recent study [44]. Bossowski et al. showed similar results in untreated Graves’ patients in whom resistin levels were higher compared to simple goiter and Hashimoto disease patients [45]. Iglesias et al also documented higher resistin in hyperthyroidism, which was explained by an increase insulin resistance in hyperthyroidism [46]. Kaplan et al. showed short-term thyroidectomy-induced hypothyroidism did not affect adipokines [47]. Our inability to document a correlation between insulin sensitivity parameters and resistin suggests the presence of alternative pathways through which resistin plays a role.
Our study is a prospective study in which the same patients with SH were evaluated after they became euthyroid. The group was homogenous in terms of metabolic and adipose tissue functions because all patients were premenopausal women, although the possibility of extrapolation of this data to men is not clear. The small sample size is another weak point of this study.
Conclusions
When hypothyroidism is present, changes occur in body temperature, food consumption, all parameters in glucose and lipid consumption, and energy metabolism. Approximately 40% of genes expressed in adipose tissue are novel and 20–30% of them can synthesize proteins. The changes in energy metabolism, even in SH status, may affect adipokine levels. The TRH-TSH pathway affects fat metabolism through a complex interaction between hypothalamus, hypophysis, thyroid, and adipose tissue [48–50]. With the presently available data it is impossible to form conclusions about changes in adipocytokines according to thyroid status. Gender and patient characteristics, degree and duration of thyroid dysfunction, antibody concentrations, metabolic effects of other hormones, and possible effects of intermediate metabolism may all be responsible for the conflicting results related to the relationship between thyroid and adipocytokine.
References
1. Cooper DS, Clinical practice. Subclinical hypothyroidism: N Engl J Med, 2001; 345(4); 260-65, pmid: 11474665
2. Hollowell JG, Staehling NW, Flanders WD, Serum TSH, T(4), and thyroid antibodies in the United States population (1988 to 1994): National Health and Nutrition Examination Survey (NHANES III): J Clin Endocrinol Metab, 2002; 87(2); 489-99, pmid: 11836274
3. Steppan CM, Bailey ST, Bhat S, The hormone resistin links obesity to diabetes: Nature, 2001; 409(6818); 307-12, pmid: 11201732
4. Patel SD, Rajala MW, Rossetti L, Disulfide-dependent multimeric assembly of resistin family hormones: Science, 2004; 304(5674); 1154-58, pmid: 15155948
5. Kusminski CM, McTernan PG, Kumar S, Role of resistin in obesity, insulin resistance and Type II diabetes: Clin Sci (Lond), 2005; 109(3); 243-56, pmid: 16104844
6. Stepien M, Rosniak-Bak K, Paradowski M, Waist circumference, ghrelin and selected adipose tissue-derived adipokines as predictors of insulin resistance in obese patients: preliminary results: Med Sci Monit, 2011; 17(11); PR13-18, pmid: 22037753
7. Harsch IA, Koebnick C, Wallaschofski H, Resistin levels in patients with obstructive sleep apnoea syndrome – the link to subclinical inflammation?: Med Sci Monit, 2004; 10(9); CR510-15, pmid: 15328483
8. Stepien M, Wlazel RN, Paradowski M, Serum concentrations of adiponectin, leptin, resistin, ghrelin and insulin and their association with obesity indices in obese normo- and hypertensive patients – pilot study: Archives of medical science: AMS, 2012; 8(3); 431-36, pmid: 22851996
9. Filkova M, Haluzik M, Gay S, Senolt L, The role of resistin as a regulator of inflammation: Implications for various human pathologies: Clin Immunol, 2009; 133(2); 157-70, pmid: 19740705
10. Krecki R, Krzeminska-Pakula M, Peruga JZ, Elevated resistin opposed to adiponectin or angiogenin plasma levels as a strong, independent predictive factor for the occurrence of major adverse cardiac and cerebrovascular events in patients with stable multivessel coronary artery disease over 1-year follow-up: Med Sci Monit, 2011; 17(1); CR26-32, pmid: 21169907
11. Pepys MB, Hirschfield GM, C-reactive protein: a critical update: J Clin Invest, 2003; 111(12); 1805-12, pmid: 12813013
12. Christ-Crain M, Meier C, Guglielmetti M, Elevated C-reactive protein and homocysteine values: cardiovascular risk factors in hypothyroidism? A cross-sectional and a double-blind, placebo-controlled trial: Atherosclerosis, 2003; 166(2); 379-86, pmid: 12535752
13. Tuzcu A, Bahceci M, Gokalp D, Subclinical hypothyroidism may be associated with elevated high-sensitive c-reactive protein (low grade inflammation) and fasting hyperinsulinemia: Endocr J, 2005; 52(1); 89-94, pmid: 15758563
14. Yaturu S, Prado S, Grimes SR, Changes in adipocyte hormones leptin, resistin, and adiponectin in thyroid dysfunction: J Cell Biochem, 2004; 93(3); 491-96, pmid: 15372626
15. Male DK, Champion BR, Pryce G, Antigenic determinants of human thyroglobulin differentiated using antigen fragments: Immunology, 1985; 54(3); 419-27, pmid: 2579024
16. Kvetny J, Heldgaard PE, Bladbjerg EM, Gram J, Subclinical hypothyroidism is associated with a low-grade inflammation, increased triglyceride levels and predicts cardiovascular disease in males below 50 years: Clin Endocrinol (Oxf), 2004; 61(2); 232-38, pmid: 15272919
17. Hueston WJ, King DE, Geesey ME, Serum biomarkers for cardiovascular inflammation in subclinical hypothyroidism: Clin Endocrinol (Oxf), 2005; 63(5); 582-87, pmid: 16268812
18. Ozcan O, Cakir E, Yaman H, The effects of thyroxine replacement on the levels of serum asymmetric dimethylarginine (ADMA) and other biochemical cardiovascular risk markers in patients with subclinical hypothyroidism: Clin Endocrinol (Oxf), 2005; 63(2); 203-6, pmid: 16060915
19. Luboshitzky R, Herer P, Cardiovascular risk factors in middle-aged women with subclinical hypothyroidism: Neuro Endocrinol Lett, 2004; 25(4); 262-66, pmid: 15361814
20. Lee WY, Suh JY, Rhee EJ, Plasma CRP, apolipoprotein A-1, apolipoprotein B and Lpa levels according to thyroid function status: Arch Med Res, 2004; 35(6); 540-45, pmid: 15631881
21. Peleg RK, Efrati S, Benbassat C, The effect of levothyroxine on arterial stiffness and lipid profile in patients with subclinical hypothyroidism: Thyroid, 2008; 18(8); 825-30, pmid: 18651824
22. Toruner F, Altinova AE, Karakoc A, Risk factors for cardiovascular disease in patients with subclinical hypothyroidism: Adv Ther, 2008; 25(5); 430-37, pmid: 18484201
23. Sharma R, Sharma TK, Kaushik GG, Subclinical hypothyroidism and its association with cardiovascular risk factors: Clin Lab, 2011; 57(9–10); 719-24, pmid: 22029187
24. Wang Z, Nakayama T, Inflammation, a Link between Obesity and Cardiovascular Disease: Mediators Inflamm, 2010; 2010; 535918, pmid: 20847813
25. Devaraj S, Singh U, Jialal I, Human C-reactive protein and the metabolic syndrome: Curr Opin Lipidol, 2009; 20(3); 182-89, pmid: 19369869
26. Unek IT, Bayraktar F, Solmaz D, Enhanced levels of soluble CD40 ligand and C-reactive protein in a total of 312 patients with metabolic syndrome: Metabolism, 2010; 59(3); 305-13, pmid: 20006362
27. Lear SA, Chen MM, Birmingham CL, Frohlich JJ, The relationship between simple anthropometric indices and C-reactive protein: ethnic and gender differences: Metabolism, 2003; 52(12); 1542-46, pmid: 14669152
28. Taddei S, Caraccio N, Virdis A, Low-grade systemic inflammation causes endothelial dysfunction in patients with Hashimoto’s thyroiditis: J Clin Endocrinol Metab, 2006; 91(12); 5076-82, pmid: 16968790
29. Bourlier V, Bouloumie A, Role of macrophage tissue infiltration in obesity and insulin resistance: Diabetes Metab, 2009; 35(4); 251-60, pmid: 19539513
30. Flier JS, Clinical review 94: What’s in a name? In search of leptin’s physiologic role: J Clin Endocrinol Metab, 1998; 83(5); 1407-13, pmid: 9589630
31. Kadowaki T, Yamauchi T, Adiponectin and adiponectin receptors: Endocr Rev, 2005; 26(3); 439-51, pmid: 15897298
32. Stouthard JM, Romijn JA, Van der Poll T, Endocrinologic and metabolic effects of interleukin-6 in humans: Am J Physiol, 1995; 268(5 Pt 1); E813-19, pmid: 7762632
33. Mohamed-Ali V, Goodrick S, Rawesh A: J Clin Endocrinol Metab, 1997; 82(12); 4196-200, pmid: 9398739
34. Koerner A, Kratzsch J, Kiess W, Adipocytokines: leptin – the classical, resistin – the controversical, adiponectin – the promising, and more to come: Best Pract Res Clin Endocrinol Metab, 2005; 19(4); 525-46, pmid: 16311215
35. Hotamisligil GS, Shargill NS, Spiegelman BM, Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance: Science, 1993; 259(5091); 87-91, pmid: 7678183
36. Savage DB, Sewter CP, Klenk ES, Resistin / Fizz3 expression in relation to obesity and peroxisome proliferator-activated receptor-gamma action in humans: Diabetes, 2001; 50(10); 2199-202, pmid: 11574398
37. McTernan CL, McTernan PG, Harte AL, central obesity, and type 2 diabetes: Lancet, 2002; 359(9300); 46-47, pmid: 11809189
38. Utzschneider KM, Carr DB, Tong J, Resistin is not associated with insulin sensitivity or the metabolic syndrome in humans: Diabetologia, 2005; 48(11); 2330-33, pmid: 16143861
39. Botella-Carretero JI, Alvarez-Blasco F, Sancho J, Escobar-Morreale HF, Effects of thyroid hormones on serum levels of adipokines as studied in patients with differentiated thyroid carcinoma during thyroxine withdrawal: Thyroid, 2006; 16(4); 397-402, pmid: 16646687
40. Krassas GE, Pontikides N, Loustis K, Resistin levels in hyperthyroid patients before and after restoration of thyroid function: relationship with body weight and body composition: Eur J Endocrinol, 2005; 153(2); 217-21, pmid: 16061827
41. Chiamolera MI, Wondisford FE, Minireview: Thyrotropin-releasing hormone and the thyroid hormone feedback mechanism: Endocrinology, 2009; 150(3); 1091-96, pmid: 19179434
42. Krassas GE, Pontikides N, Loustis K, Resistin levels are normal in hypothyroidism and remain unchanged after attainment of euthyroidism: relationship with insulin levels and anthropometric parameters: J Endocrinol Invest, 2006; 29(7); 606-12, pmid: 16957408
43. Luvizotto RA, Sibio MT, Olimpio RM, Supraphysiological triiodothyronine doses diminish leptin and adiponectin gene expression, but do not alter resistin expression in calorie restricted obese rats: Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme, 2011; 43(7); 452-57, pmid: 21557150
44. El Gawad SS, El Kenawy F, Mousa AA, Omar AA, Plasma levels of resistin and ghrelin before and after treatment in patients with hyperthyroidism: Endoc Pract, 2012; 18(3); 376-81
45. Bossowski A, Sawicka B, Szalecki M, Analysis of serum adiponectin, resistin and leptin levels in children and adolescents with autoimmune thyroid disorders: J Pediatr Endocrinol Metab, 2010; 23(4); 369-77, pmid: 20583542
46. Iglesias P, Alvarez Fidalgo P, Codoceo R, Diez JJ, Serum concentrations of adipocytokines in patients with hyperthyroidism and hypothyroidism before and after control of thyroid function: Clin Endocrinol (Oxf), 2003; 59(5); 621-29, pmid: 14616887
47. Kaplan O, Uzum AK, Aral H, Short Term Thyroidectomy-Induced Hypothyroidism Causes No Change on Serum Adipokine Concentrations: Endocr Pract, 2012; 1-19
48. Nannipieri M, Cecchetti F, Anselmino M, Expression of thyrotropin and thyroid hormone receptors in adipose tissue of patients with morbid obesity and/or type 2 diabetes: effects of weight loss: Int J Obes (Lond), 2009; 33(9); 1001-6, pmid: 19636322
49. Kim MS, Small CJ, Stanley SA, The central melanocortin system affects the hypothalamo-pituitary thyroid axis and may mediate the effect of leptin: J Clin Invest, 2000; 105(7); 1005-11, pmid: 10749579
50. Kok P, Roelfsema F, Frolich M, Spontaneous diurnal thyrotropin secretion is enhanced in proportion to circulating leptin in obese premenopausal women: J Clin Endocrinol Metab, 2005; 90(11); 6185-91, pmid: 16091498
In Press
Clinical Research
Institutional and Regional Variations in Access to Clinical Trials and Next-Generation Sequencing in Turkis...Med Sci Monit In Press; DOI: 10.12659/MSM.951027
Clinical Research
Low-Intensity Blood Flow-Restricted Multi-Joint Exercise Improves Muscle Function in Patients With Patellof...Med Sci Monit In Press; DOI: 10.12659/MSM.950516
Review article
Musculoskeletal Ultrasound and MRI in the Evaluation of Chemotherapy-Induced Peripheral Neuropathy: A ReviewMed Sci Monit In Press; DOI: 10.12659/MSM.951283
Clinical Research
Sensory Processing, Dissociation, and Affective Symptoms in Misophonia: A Cross-Sectional Study of 35 AdultsMed Sci Monit In Press; DOI: 10.12659/MSM.950938
Most Viewed Current Articles
17 Jan 2024 : Review article 10,187,196
Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron VariantDOI :10.12659/MSM.942799
Med Sci Monit 2024; 30:e942799
13 Nov 2021 : Clinical Research 3,708,487
Acceptance of COVID-19 Vaccination and Its Associated Factors Among Cancer Patients Attending the Oncology ...DOI :10.12659/MSM.932788
Med Sci Monit 2021; 27:e932788
14 Dec 2022 : Clinical Research 2,341,643
Prevalence and Variability of Allergen-Specific Immunoglobulin E in Patients with Elevated Tryptase LevelsDOI :10.12659/MSM.937990
Med Sci Monit 2022; 28:e937990
16 May 2023 : Clinical Research 706,524
Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...DOI :10.12659/MSM.940387
Med Sci Monit 2023; 29:e940387